Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $695,199.36 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Jeffrey Poulton sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president owned 59,802 shares of the company’s stock, valued at $18,543,404.16. This trade represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Alnylam Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ:ALNY opened at $339.37 on Friday. The firm has a market capitalization of $45.01 billion, a PE ratio of 198.46 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The firm’s 50-day moving average is $368.11 and its two-hundred day moving average is $423.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue for the quarter was up 84.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.65) EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and kept a buy rating, signaling meaningful upside versus the current quote. Canaccord price-target raise
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $510 price target (~50% above the current level), providing a bullish benchmark for upside expectations. HC Wainwright note
• Positive Sentiment: Freedom Capital upgraded ALNY from Hold to Strong-Buy, adding to positive analyst momentum. Freedom Capital upgrade
• Positive Sentiment: Large institutional buying reported in Q4 (notable stake increases by Guggenheim, Caisse, Schonfeld and AQR) suggests strong institutional conviction and supports liquidity/demand for the shares.
• Neutral Sentiment: Short-interest entries in the feed show zero/NaN and a 0.0 days-to-cover figure — this looks like a data/reporting artifact rather than new shorting pressure; treat as non-actionable until exchange-confirmed data appears.
• Neutral Sentiment: Analysts collectively trimmed some near-term targets but still express confidence in 2026 growth — mixed model adjustments rather than a broad sell-off. Analysts trim targets
• Negative Sentiment: Several insiders sold shares this week, including CEO Yvonne Greenstreet (~6,958 shares) and multiple senior executives (Kevin Fitzgerald, Pushkal Garg, others). Large, clustered insider sales can weigh on sentiment even if they are routine or pre-planned. CEO sale SEC filing
• Negative Sentiment: Chardan trimmed its price target to $425 (a modest downgrade relative to some peers), and ALNY’s most recent quarterly report showed an EPS miss (Feb. 12) despite strong revenue growth — reminders of execution/near-term margin risk. Chardan target cut

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV lifted its position in shares of Alnylam Pharmaceuticals by 2.6% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 11,786 shares of the biopharmaceutical company’s stock worth $4,687,000 after buying an additional 302 shares during the last quarter. Raymond James Financial Inc. lifted its position in Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Raymond James Financial Inc. now owns 388,705 shares of the biopharmaceutical company’s stock valued at $154,432,000 after acquiring an additional 11,411 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $267,000. Mackenzie Financial Corp grew its holdings in shares of Alnylam Pharmaceuticals by 26.8% during the fourth quarter. Mackenzie Financial Corp now owns 12,395 shares of the biopharmaceutical company’s stock worth $4,914,000 after purchasing an additional 2,622 shares during the last quarter. Finally, Empowered Funds LLC increased its position in shares of Alnylam Pharmaceuticals by 353.5% during the fourth quarter. Empowered Funds LLC now owns 19,431 shares of the biopharmaceutical company’s stock worth $7,727,000 after purchasing an additional 15,146 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Needham & Company LLC decreased their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Truist Financial decreased their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Barclays assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday. Finally, Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.